CNCarole Nagant

Carole Nagant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carole Nagant has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Francis Corazza

    Immunology Department Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium

    3 shared publications
  • Tatiana Besse-Hammer

    2 shared publications
  • Alice Ferster

    Department of Hematology Oncology Ho ˆpital Universitaire des Enfants Reine Fabiola Universite ´libre de Bruxelles Brussels Belgium

    1 shared publication
  • Amandine Nachtergael

    Unit of Therapeutic Chemistry and Pharmacognosy, Faculty of Medicine, Pharmacy and Biomedical Sciences, University of Mons (UMONS), Avenue du Champ de Mars, 25, 7000 Mons, Belgium

    1 shared publication
  • Anca Reschner

    Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium

    1 shared publication
  • André Efira

    Affiliation Department of Hematology Oncology, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

    1 shared publication

Latest Publications

  • Open Access

    A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus

    by Carole Nagant, Maxime Taghavi, Hasnae Ben Kacem Ziani, Nathalie Ghorra, Valérie Badot, Sarah Parmentier, Francis Corazza

    Objectives: Anti‐dsDNA antibodies are established biomarkers in systemic lupus erythematosus (SLE), yet the clinical utility of conventional assays remains limited by variable analytical performance. We evaluated a novel Fibre‐Optic Surface Plasmon Resonance (FO‐SPR) biosensor for real‐time profiling of anti‐dsDNA antibody–antigen interactions and investigated whether kinetic parameters are associated with disease severity, particularly lupus nephritis (LN). Methods: Sera from 26 SLE patients (including 12 with LN), 14 disease controls and 16 healthy donors were analysed using FO‐SPR biosensors coated with biotinylated dsDNA. The sensors generated real‐time kinetic profiles from which maximum binding response ( B max ), association rate and dissociation constant were computed. FO‐SPR kinetic results were compared with a conventional chemiluminescent anti‐dsDNA assay (CLIA) and correlated with disease activity and renal involvement. Results: The FO‐SPR platform enabled reliable detection of anti‐dsDNA antibodies and clearly distinguished SLE patients with renal involvement: Eight of 12 LN patients showed B max values above the 90th percentile of the non‐SLE control group. In these patients, kinetic parameters revealed high‐affinity anti‐dsDNA profiles characterised by significantly higher association rates and maximal shifts and lower dissociation constants. The AUC‐ROC for SPR‐derived affinity parameters was 0.82 ( P = 0.006), outperforming the CLIA assay to discriminate lupus patients with versus without nephritis. Furthermore, FO‐SPR binding responses correlated with disease activity score in LN. Conclusion: This study highlights the value of an innovative FO‐SPR biosensor for real‐time characterisation of anti‐dsDNA antibody affinity. The kinetic profiles captured by this platform provide clinically relevant insights, particularly for distinguishing LN patients from other SLE phenotypes.


  • Open Access

    Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases

    by Céline La, Julie Smet, Carole Nagant, Muhammad Soyfoo

    Anti-Ku antibodies are rare autoantibodies associated with connective tissue diseases (CTDs), but their clinical significance remains poorly understood due to limited studies. Semi-quantitative immunodot assays yield positive, negative, or borderline results, with the clinical relevance of borderline findings remaining unclear. The purpose of this study is to characterize the clinical spectrum of anti-Ku-positive patients and evaluate the clinical significance of anti-Ku-borderline results in CTD management. A retrospective cohort study was conducted at Hôpital Erasme, including all patients with anti-Ku-positive or borderline results, over a 10-year period. Clinical and biological data were collected from medical records and analyzed for disease associations, organ involvement, and outcomes. Among 47 anti-Ku-positive patients, systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) were the most common diagnoses. Interstitial lung disease (ILD) occurred in 23.4% and renal involvement in 12.8% of patients. Cytopenia was significantly associated with glomerulonephritis. Organ damage, particularly pulmonary and renal involvement, correlated with increased mortality. In the borderline group (n = 33), SLE and SS remained the predominant diagnoses. During follow-up, three patients died (all with isolated ILD without associated CTD), one required chronic dialysis, and one underwent lung transplantation. ILD was present in 7/22 (31.8%) borderline patients, and renal involvement in 7/32 (21.9%). This study demonstrates significant associations between anti-Ku antibodies and organ damage, with increased mortality risk. The high prevalence of pulmonary and renal involvement in anti-Ku-borderline patients suggests that these results carry substantial clinical significance and should prompt comprehensive CTD evaluation. These findings support treating borderline anti-Ku results with the same clinical vigilance as positive results, given their similar association with severe organ involvement and adverse outcomes.


  • Open Access

    A case of anti-HMGCR myopathy in a patient with breast cancer and anti-Th/To antibodies

    by Mohammad Yassine Chérif, Ioannis Raftakis, Marjolaine Weynand, Elena Dragan, Carole Nagant, Sophie Lecomte, Valérie Badot

    Statins competitively inhibit the activity of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is a key enzyme in cholesterol synthesis. These are effective drugs for the management of cardiovascular disease and are generally well tolerated but several side effects have been reported. Muscular adverse symptoms are various and, rarely, statin exposure may lead to authentic immune-mediated necrotizing myopathy (IMNM), namely anti-HMGCR myopathy. However, cases of IMNM associated with cancer have been described. We discuss herein a case of IMNM in a patient with breast cancer previously exposed to statins and with the presence of anti-Th/To antibodies without clinical correlation.


  • Open Access

    Tetanus seroprotection in people living with HIV: Risk factors for seronegativity, evaluation of medical history and a rapid dipstick test

    by Cathy Gobert, Celine Van Hauwermeiren, Catherine Quoidbach, Anca Reschner, Coca Necsoi, Asma Benslimane, Carole Nagant, Sigi Van Den Wijngaert, Marc Delforge, Francis Corazza, et al.


  • Open Access

    A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer

    by Carole Nagant, Fanny Ponthieux, Julie Smet, Nicolas Dauby, Virginie Doyen, Tatiana Besse-Hammer, David De Bels, Evelyne Maillart, Francis Corazza


  • Open Access

    Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease

    by Carole Nagant, Cyril Barbezange, Laurence Dedeken, Tatiana Besse-Hammer, Isabelle Thomas, Bhavna Mahadeb, André Efira, Alice Ferster, Francis Corazza

    Patients suffering from Sickle Cell Disease (SCD) are at increased risk for complications due to influenza virus. Annual influenza vaccination is strongly recommended but few clinical studies have assessed its immunogenicity in individuals with SCD. The aim of this study was to explore the biological efficacy of annual influenza vaccination in SCD patients by characterizing both their humoral and cell-mediated immunity against influenza antigen. We also aimed to investigate these immunological responses among SCD individuals according to their treatment (hydroxyurea (HU), chronic blood transfusions (CT), both HU and CT or none of them). Seventy-two SCD patients (49 receiving HU, 9 on CT, 7 with both and 7 without treatment) and 30 healthy controls were included in the study. All subjects received the tetravalent influenza α-RIX-Tetra® vaccine from the 2016–2017 or 2017–2018 season. Protective anti-influenza HAI titers were obtained for the majority of SCD patients one month after vaccination but seroconversion rates in patient groups were strongly decreased compared to controls. Immune cell counts, particularly cellular memory including memory T and memory B cells, were greatly reduced in SCD individuals. Functional activation assays confirmed a poorer CD8+ T cell memory. We also document an imbalance of cytokines after influenza vaccination in SCD individuals with an INFγ/IL-10 ratio (Th1-type/Treg-type response) significantly lower in the SCD cohort. SCD patients undergoing CT showed altered immune regulation as compared to other treatment subgroups. Altogether, the cytokine imbalance, the high regulatory T cell levels and the low memory lymphocyte subset levels observed in the SCD cohort, namely for those on CT, suggest a poor ability of SCD patients to fight against influenza infection. Nevertheless, our serological data support current clinical practice for annual influenza vaccination, though immunogenicity to other vaccines involving immunological memory might be hampered in SCD patients and should be further investigated.


  • Easy discrimination of hematogones from lymphoblasts in B‐cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio

    by Carole Nagant, Daniele Casula, Anne Janssens, Vo Thanh Phuong Nguyen, Brigitte Cantinieaux

    Introduction: The discrimination of leukemia lymphoblasts (LB) in diagnosis and follow‐up of B‐cell progenitor acute lymphoblastic leukemia (BCP‐ALL) by multiparameter flow cytometry (MFC) may be difficult due to the presence of hematogones (HG). The aim of this study was to compare lymphoblasts of BCP‐ALL and HG for the expression of the most discriminating antigens.Methods: A total of 82 bone marrow samples (39 BCP‐ALL and 43 patients with HG) were analyzed using MFC. Mean fluorescence intensity (MFI) was measured for ten markers commonly used in hematology laboratories: CD45, CD19, CD10, CD34, CD38, CD20, CD22, CD58, CD81, and CD123. Statistical comparison of the MFI between LB and HG was performed. The presence on LB of aberrant expression of myeloid and/or T‐cell markers was also investigated.Results: Qualitative pattern expression of antigens showed overexpression on LB of CD58, CD22, CD34, CD10 and underexpression of CD81, CD45, CD38 when compared to HG. Expression of CD123 was positive in 34% of BCP‐ALL LB and always absent on HG. Aberrant antigen expression (myeloid and/or T‐cell marker) including CD123 was observed in 58% of BCP‐ALL patients. The use of a MFI antigen ratio of the most discriminating markers (CD81/CD58) (analysis of variance, P < 0.005) increased the distinction of LB versus HG with a high specificity and sensitivity as demonstrated by the use of ROC curve analysis (AUC of CD81/CD58: 0.995).Conclusion: We demonstrate in this study that routine use of the MFI antigen ratio (CD81/CD58) in addition to the MFC evaluation using WHO classical criteria appears to be an efficient approach to discriminate LB from HG.


  • Low prevalence of mupirocin resistance in BelgianStaphylococcus aureusisolates collected during a 10 year nationwide surveillance: Table 1.

    by Carole Nagant, Ariane Deplano, Claire Nonhoff, Ricardo De Mendonça, Sandrine Roisin, Magali Dodémont, Olivier Denis


  • Contribution of the production of quormones to some phenotypic characteristics of Pseudomonas aeruginosa clinical strains

    by C. Nagant, M. Seil, A. Nachtergael, S. Dulanto, J. P. Dehaye

    The contribution of quorum sensing in some phenotypic and pathogenic characteristics of Pseudomonas aeruginosa was studied. The production of acylhomoserine lactones (AHL) by planktonic cultures of eight clinical and reference strains of P. aeruginosa was evaluated using two biosensors. The adhesion of the bacteria on a surface (Biofilm Ring Test ®, BFRT), their capacity to develop a biofilm (crystal violet staining method, CVSM), their sensitivity to tobramycin and their secretion of proteases or of rhamnolipids were also measured. The production and the release of AHL widely varied among the eight strains. An analysis of the extracts by TLC showed that 3-oxo-C8-HSL, 3-oxo-C10-HSL and 3-oxo-C12-HSL were released by the five strains producing the highest amount of C≥6-HSL. The genes lasI and lasR involved in the synthesis and response to 3-oxo-C12-HSL were detected in the genomes of all strains. Two clinical strains had deletions in the lasR gene leading to truncation of the protein. One subpopulation of the PAO1 strain had a major deletion (98 bp) of the lasR gene. Strains with significant mutations of lasR secreted the lowest amount of AHL, probably due to deficiencies in the self-induction and amplification of the synthesis of the lactone. These strains formed a biofilm with low biomass. C4-HSL production also differed among the strains and was correlated with rhamnolipid production and biofilm formation. Whereas the production of AHL varied among P. aeruginosa strains, few correlations were observed with their phenotypic properties except with their ability to form a biofilm.


  • Open Access

    Study of the effect of antimicrobial peptide mimic, CSA‐13, on an established biofilm formed by Pseudomonas aeruginosa

    by Carole Nagant, Betsey Pitts, Philip S. Stewart, Yanshu Feng, Paul B. Savage, Jean‐Paul Dehaye

    The formation of a Pseudomonas aeruginosa biofilm, a complex structure enclosing bacterial cells in an extracellular polymeric matrix, is responsible for persistent infections in cystic fibrosis patients leading to a high rate of morbidity and mortality. The protective environment created by the tridimensional structure reduces the susceptibility of the bacteria to conventional antibiotherapy. Cationic steroid antibiotics (CSA)‐13, a nonpeptide mimic of antimicrobial peptides with antibacterial activity on planktonic cultures, was evaluated for its ability to interact with sessile cells. Using confocal laser scanning microscopy, we demonstrated that the drug damaged bacteria within an established biofilm showing that penetration did not limit the activity of this antimicrobial agent against a biofilm. When biofilms were grown during exposure to shear forces and to a continuous medium flow allowing the development of robust structures with a complex architecture, CSA‐13 reached the bacteria entrapped in the biofilm within 30 min. The permeabilizing effect of CSA‐13 could be associated with the death of the bacteria. In static conditions, the compound did not perturb the architecture of the biofilm. This study confirms the potential of CSA‐13 as a new strategy to combat persistent infections involving biofilms formed by P. aeruginosa.